Investors

Filament Health is a clinical-stage natural psychedelic drug development company

We are building a comprehensive platform to support the treatment of mental health conditions through the administration of natural psychedelic drug candidates into FDA authorized human clinical trials. These drug candidates have been grown and manufactured by our wholly-owned subsidiary, Psilo Scientific.

Filament Health trades on the OTCQB Venture Market (OTCQB:FLHLF), Canada’s NEO Exchange (NEO:FH), and the Frankfurt Stock Exchange (FSE:7QS).

symbol
securityname
$
closeprice
lastupdatedate
lastupdatetime
FLHLF: OTCQBBid: 0.0565 Ask: 0.08
Source: OTC Markets Group | TermsReal-Time: 3:50:02 PM EDT
Corporate Presentation
Annual General Meeting
Investor Events
Recent investor events offering insight into Filament’s business activities, clinical trials, and psychedelic drug development facility.
Virtual Update from Filament CEO, April 2022
Investor Events
Recent investor events offering insight into Filament’s business activities, clinical trials, and psychedelic drug development facility.
October Virtual CEO Q&A
August Virtual Investor Event